Pharmafile Logo

patient advocates

- PMLiVE

Alexion and Aide Health launch app for people with rare diseases

More than 3.5 million people in the UK live with a rare condition

- PMLiVE

Shionogi to acquire IntraBio in deal worth $2bn

The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities

- PMLiVE

Ogsiveo recommended by NICE to treat rare soft tissue tumours

Desmoid tumours are rare soft tissue tumours that can grow aggressively into nearby tissues

- PMLiVE

Pharma-Exclusive Webinar: Redefining Engagement in the AI Era

Join Impetus Digital's pharma-exclusive webinar to discover how compliant AI tools and virtual workflows can elevate static programs into high-retention, interactive experiences without enterprise overhead.

Impetus Digital

- PMLiVE

LEO Pharma acquires rights for dersimelagon from Tanabe Pharma

The company will pay $435m in up front and near-term milestone payments

- PMLiVE

Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.

Impetus Digital

London

5 key takeaways from the Patient Centricity and Engagement Conference

Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.

Cuttsy + Cuttsy

Woman with headache

It’s time to stop calling adverse events ‘manageable’

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.

Cuttsy + Cuttsy

- PMLiVE

LEO Pharma to acquire Replay gene therapy platform

The acquisition will advance innovation for patients with rare skin diseases

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links